Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 13/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10218438 | 0.89 | MAPT (0.58) | P2RY1NPC1MAPTRAB9AKDM4E | |
| SCHEMBL5459132 | 0.86 | MAPT (0.55) | P2RY1NPC1MAPTRAB9AKIT | |
| SCHEMBL5460083 | 0.85 | RAB9A (0.77) | P2RY1NPC1MAPTRAB9AKDM4E | |
| SCHEMBL5460745 | 0.84 | MAPT (0.56) | P2RY1NPC1MAPTRAB9AKDM4E | |
| SCHEMBL5455863 | 0.82 | KMT2A (0.62) | P2RY1NPC1MAPTRAB9AKDM4E | |
| SCHEMBL5465589 | 0.81 | NAMPT (0.58) | P2RY1NPC1MAPTRAB9A | |
| SCHEMBL5465662 | 0.81 | NPC1 (0.59) | P2RY1NPC1MAPTRAB9AKDM4E | |
| SCHEMBL5460057 | 0.79 | P2RY1 (0.57) | P2RY1NPC1MAPTRAB9ANPSR1 | |
| SCHEMBL5460707 | 0.79 | MT-CO2 (0.61) | P2RY1NPC1MAPTRAB9AKDM4E | |
| SCHEMBL5462720 | 0.78 | RAB9A (0.62) | P2RY1NPC1MAPTRAB9AMT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | P2RY1 3474/4885NPC1 1089/4885MAPT 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.